Press Releases
FGA Trust Commits $7 Million to Accelerate Research For Diffuse Midline Glioma
FGA Trust commits $7 million to accelerate research for diffuse midline glioma
PNOC Foundation Welcomes Pediatric Cancer Advocate Rob Stuart to Its Board of Directors
Rob Stuart brings community-rooted fundraising experience to PNOC Foundation's board
First Patient Enrolled in PNOC035 Clinical Trial for Recurrent ATRT
PNOC Foundation celebrates the launch of PNOC035, a groundbreaking clinical trial for children, adolescents, and young adults with recurrent or progressive atypical teratoid rhabdoid tumor (ATRT).
For Families Facing a Deadly Brain Cancer, Scientific Progress Can’t Come Soon Enough
The New York Times: For Families Facing a Deadly Brain Cancer, Scientific Progress Can’t Come Soon Enough, July 16, 2026
PNOC Foundation Appoints Biopharma Executive Jeremy Bender to Its Board of Directors
Biopharma leader and longtime PNOC collaborator Jeremy Bender, brings firsthand experience turning pediatric brain cancer research into approved treatments.
PNOC Foundation Invites United MileagePlus Members to Donate Miles to Help Pediatric Brain Cancer Research
Your United Airlines miles could help the world’s leading pediatric brain tumor experts collaborate on lifesaving treatments for the deadliest childhood cancers.
The Max Pound Foundation deepens PNOC support with additional $50,000 gift
The Pediatric Neuro-Oncology Consortium (PNOC) is honored to announce an additional $50,000 gift from the Max Pound Foundation, continuing and expanding the foundation’s longstanding commitment to accelerating progress for children with brain cancer.
PNOC Foundation launches $50 million “Lose No Child” Campaign
PNOC Foundation announces the launch of their Lose No Child: a $50 million campaign to accelerate progress against pediatric brain cancer.
ONC201 FDA drug approval for Diffuse Midline Glioma
FDA grants accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.
Measles Oncolytic Virus as an Immunotherapy
Clinical Cancer Research Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005, August, 2025
PNOC Foundation Enhances Donation Options
PNOC Foundation Enhances Donation Options to Accelerate Pediatric Brain Cancer Research
Measles Oncolytic Virus as an Immunotherapy (Copy)
Pediatric Neuro-Oncology Consortium Partnership Receives Prestigious ARPA-H Multi-Million Dollar Grant for Groundbreaking RADIANT Project, to Rapidly Advance Treatments for Children With Brain Tumors
Tovorafenib FDA Approval for low-grade glioma
PNOC Foundation announces FDA approval of tovorafenib (day101) in partnership with pnoc scientific consortium and day one biopharmaceuticals
Neuro-Oncology Rational combination platform trial design
Rational combination platform trial design for children and young adults with diffuse midline glioma